Previous studies found that high expression of ARL4C was found in low-grade glioblastoma (GBM) and was correlated with poorer progression-free survival (PFS) and overall survival (OS) in patients (Liu et al., 2022). This evidence concerns the gene ARL4C and glioblastoma.